- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Private Label Biosimilars
The expert panel discusses the greater potential for private label biosimilars.
EP: 1.Biologics Utilization Impacting US Health Care Spending
EP: 2.Current Landscape of Biosimilar Use in US Healthcare Space
EP: 3.Interchangeability Impacting Biosimilar Uptake
EP: 4.The Impact of Payer Coverage and Reimbursement on Biosimilars
EP: 5.Navigating Biosimilar Uptake in New Patients
EP: 6.Economic Impacts and Pricing Strategies Surrounding Biosimilars
EP: 7.Private Label Biosimilars
EP: 8.Biosimilars in the Commercial Sector
EP: 9.The Influence of Employer Preferences And Adoption of Biosimilars
EP: 10.Out of Pocket Costs Associated with Biosimilar Use
EP: 11.Unmet Needs and Future Initiatives
EP: 12.Ideal Goals for Biosimilar Utilization
EP: 13.Foreseeable Biosimilar Trends
EP: 14.Legislative Support for Biosimilars
EP: 15.Key Takeaways for Biosimilar Utilization
Video content above is prompted by the following questions:
- Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
5 Key Drug Approvals and CRLs in 2024
December 27th 2024In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades.
Read More
From Approval to Practice: Addressing the Hurdles in Biosimilar Integration
December 12th 2024Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.
Read More
